FDA approves Votrient for advanced soft tissue sarcoma
On April 26, the U.S. Food and Drug Administration (FDA) approved Votrient (pazopanib) to treat patients with advanced soft tissue sarcoma who have previously…
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.